Roivant Sciences
UPDATE 1-Moderna shares fall after judge sides with Arbutus in patent fight
Moderna shares fall after judge sides with Arbutus in patent fight. Shares of Moderna MRNA.O fell 4% in afternoon trading. A U.S. Judge interpreted parts of the patents in ways that strengthened Ar butus' case. The lawsuit is related to Moderna's blockbuster COVID-19 vaccines.
Reuters · 04/03 18:48
BUZZ-Moderna slides after judge sides with Arbutus in patent fight
U.S. Judge sides with Arbutus in patent infringement lawsuit related to MRNA's blockbuster vaccines. Shares of Moderna slide 3.5% to $100 after the news. MRNA is a joint venture of MRNA and Roivant Sciences. Ar butus shares up 12.1% in after-hours trading.
Reuters · 04/03 18:15
Reuters · 04/03 10:06
BUZZ-U.S. STOCKS ON THE MOVE-Paychex, ChampionX, EV stocks
Wall Street's main indexes drop on Tuesday. Dow Jones Industrial Average was down 1.24% at 39,076.51. Top three S&P 500 percentage gainers: GE, Phillips 66 and Freeport-McMoran. Biggest decliners were Tesla and UnitedHealth Group.
Reuters · 04/02 17:56
BUZZ-U.S. STOCKS ON THE MOVE-VirTra, GE Vernova, Blackstone
U.S. Stock indexes fell on Tuesday. The Dow Jones Industrial Average was down 1.24% and the S&P 500 and Nasdaq Composite were also down. Investors grew concerned about the possibility of fewer interest rate cuts than expected from the Federal Reserve. GE Vernova was one of the top gainers on the NYSE.
Reuters · 04/02 16:27
BUZZ-U.S. STOCKS ON THE MOVE-PVH, Verve Therapeutics, Canoo
Wall Street set to open lower on Tuesday. Dow e-minis down 0.81% ahead of comments from Federal Reserve policymakers. Top three NYSE percentage gainers: Ihuman, Verve Therapeutics, Canoo. PVH Corp down 21.9% premarket; Humana down 11.2%.
Reuters · 04/02 13:26
BUZZ-Roivant jumps after anti-inflammatory drug succeeds in mid-stage study
Roivant Sciences shares up 7.4% at $11.20 in premarket trading. Company says its experimental drug to treat -infectious uveitis succeeds in mid-stage study. Anti-inflammatory drug helped reduce symptoms of the inflammatory eye disease in the study.
Reuters · 04/02 12:08
UPDATE 2-Roivant's anti-inflammatory drug shows promise in mid-stage study
Roivant Sciences' shares up 8% after drug shows promise in mid-stage study. The drug, brepocitinib, helped reduce symptoms of the inflammatory eye disease uveitis. Analyst say drug could benefit patients more than Abbvie's Humira. Roivant expects drug to be multi-billion dollar opportunity.
Reuters · 04/02 11:21

Webull offers Roivant Sciences stock information, including NASDAQ: ROIVW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ROIVW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ROIVW stock methods without spending real money on the virtual paper trading platform.